Bacteriuria with Group B Streptococci (GBS) during pregnancy may constitute a marker for a high load of genital tract colonization with GBS, and it constitutes a risk factor for early-onset GBS disease (EOGBS) [1] [2] [3] . Therefore, identification of GBS in urine might be a useful screening tool for identification of women at risk of transferring GBS to their infant at birth.
We know only little about the association between the antepartum GBS-urinary colony count and the load of GBS in the vagina intrapartum. If this association is strong, quantification of GBS in the urine may constitute an effective tool for assessing the risk of EOGBS and minimizing the number of women who should be screened for vaginal GBS colonization intrapartum by a polymerase chain reaction (PCR) test. If the quantitative association is very strong, the antepartum GBS screening of urine might even replace the intrapartum vaginal PCR-GBS test, which is usually not quantitative [4, 5] and is perhaps too sensitive, thus finding small and clinical insignificant numbers of GBS in the vagina.
The aims of this study were to assess the performance of screening for GBS in urine at 35-37 weeks' gestation to identify women with vaginal GBS colonization during labor, and furthermore, to evaluate whether the urinary GBS colony-count provides further information regarding the load of GBS in the vagina.
Material and Methods

Study design
In this prospective observational study, we included 902 pregnant women at a gestational age of 29 weeks [4] . Detailed information on oral antibiotic use during pregnancy was obtained from the registered data in medical records and delivered from the Danish Medical Agency's Register of non-hospitalized patient use, which included records on all drug prescriptions filed at any Danish pharmacy [6] .
Inclusion criteria:
 Pregnant women attending the prenatal Clinic at Lillebaelt Hospital, Kolding, Denmark.
All pregnant women in the catchment area of Lillebaelt Hospital give birth at this clinic, as there are no private or other public alternatives. Only very complicated pregnancies like extreme preterm births are referred to University Hospitals.
Exclusion criteria:
 Women treated with antibiotics after 35 weeks´ gestation.
 Preterm labor (before 37 +0 weeks gestation).
 Age under 18 years.
 Women with a communication barrier such as language or mental health conditions. Hospital, Vejle, Denmark. All GBS-like colonies (identified by their orange color on Granada agar plates) were routinely confirmed as Streptococcus agalactiae using the Microflex LT ™ MALDI-TOF system (Bruker Daltonik, Germany). Growth was classified semi-quantitatively as plates having only growth of a few GBS colonies (1+), some (2+) or many (3+). Twenty-seven culture tests were mistakenly not recorded with a semi-quantitative assessment result: 21 were urine culture negative at 35-37 weeks´ gestation, 6 were urine culture positive, of which 2 had a colony count <10 4 CFU/mL and 4 had a colony count =10 4 CFU/mL.
Collection and culture of specimens
Ethics
The study was approved by the Regional Scientific Ethical Committees for Southern Denmark (S-20130089) and the Danish Data Protection Agency (2008-58-0035). All participants provided written informed consent. 
Statistics
Results
Within the population of 902 unselected pregnant women, the rate of GBS-uria at 35-37 weeks' gestation (GBSurine 35-37 weeks) was 5.9% (53/902), whereas the rate of GBS in vagina at birth (GBSvagina birth) was 11.5% (104/902). Those with and without GBSurine 35-37 weeks did not differ concerning age of the mother, parity, body mass index, and tobacco use ( Table 1) .
The sensitivity of GBSurine 35-37 weeks to predict any degree of GBSvagina birth was 30% (31/104), and the corresponding positive predictive value (PPV) was 59% (31/53). The negative predictive value (NPV) was 91% (776/849).
The GBS colony count in the case of GBSurine 35-37 weeks was further informative. Thus, 6/17 (35%) with GBSurine 35-37 weeks was <10 4 CFU/mL had GBSvagina birth ( Table 3 ). The corresponding figures for 10 4 CFU/mL were 19/27 (70%), and for >10 4 CFU/mL 6/9 (67%). A high load (+3) GBSvagina birth was predicted with a sensitivity of 52% (17/33) by GBSurine 35-37 weeks ( Table 3) .
GBSvagina 35-37 weeks predicted GBSvagina birth with a sensitivity of 64% (67 of 104 cases; data not shown). Furthermore, GBSurine 35-37 weeks predicted GBSvagina 35-37 weeks with a sensitivity of 48% (48/100) and a specificity of 99% (797/802).
A C C E P T E D M A N U S C R I P T
Discussion
In a cohort of 902 unselected pregnant women, we found that GBSurine 35-37 weeks predicted any degree of GBSvagina birth with a sensitivity of only 30% and a high load (+3) GBSvagina birth with a sensitivity of 52%. However, the corresponding negative predictive value (NPV) of GBSurine 35-37 weeks was 91%.
The strength of our study is the prospective cohort design with a quantitative assessment of possible GBS bacteriuria antepartum for all women combined with a semi-quantitative assessment of GBS in the vagina at birth. Furthermore, a relatively high number of unselected pregnant women participated in the study. It is a minor limitation that the assessments of 27 intrapartum vaginal swabs in the study were not assessed semi-quantitatively.
The relatively low sensitivity of GBSurine 35-37 weeks in predicting vaginal GBSvagina birth can be explained by at least two factors. Firstly, GBSurine 35-37 weeks predicts only 48% (GBSvagina 35-37 weeks), i.e. only half the women with GBS in the vagina have GBS in the urine on the day of sampling.
Secondly, even GBSvagina 35-37 weeks predicted only 64% of GBSvagina birth, i.e. at least 36% changed their vaginal GBS status within these few weeks, a substantial change which has also been noted by others [7] .
The prevalence of GBSurine was comparable to that reported in other studies [8] [9] [10] [11] . Our findings confirm the findings of Perez-Moreno et al. (2017) in their prospective study on GBSurine during pregnancy as a risk factor for maternal intrapartum colonization. They found a sensitivity of 41%, a specificity of 95%, a PPV of 59%, and NPV of 95% of GBSurine 35-37 weeks in predicting GBSvagina birth [12] . The authors concluded that GBS bacteriuria is a risk factor for intrapartum colonization, irrespective of urinary GBS concentration or colonization status at late gestation [12] . These Several guidelines recommend intrapartum antibiotics prophylaxis in case of significant GBSurine during pregnancy, as this condition is regarded as a sign of high load of genital tract colonization [13] [14] [15] . However, the guidelines do not agree on the definition of significant GBSurine. Thus, RCOG and a recent European guideline define significant GBSurine as any degree of GBSurine [13, 14] , whereas CDC uses a definition of ≥ 10 4 CFU/mL [16] .
Our findings do not support the use of GBSurine 35-37 weeks as an isolated risk marker for EOGBS, and as a result, for identification of laboring women who should be offered prophylactic penicillin at birth. However, GBSurine 35-37 weeks seems to perform better than other risk markers like gestational age at birth <37 weeks [17] , duration of rupture of membranes >18 hours [18] , temperature >38.0 °C [19] [20] [21] , or delivery of a previous infant with GBS-specific EOS [22, 23] .
Therefore, EOGBS-prevention strategies offering an intrapartum GBS test only to mothers at risk of having a new-born acquiring EOGBS could benefit from the inclusion of this risk marker. This would probably substantially increase the sensitivity of a selective intrapartum GBS screening strategy Rapid tests for vaginal colonization by GBS are based on PCR. They do not offer quantitative results and they may be too sensitive, thus identifying low loads of vaginal GBS colonization, which is likely to be associated with a low risk of EOGBS. A number of studies therefore suggest through indirect observation that low level carriage of GBS is associated with a reduced transmission rate compared to that in patients with higher bacterial burdens [24, 25] .
We conclude that GBSurine 35-37 weeks is associated with a high load of GBSvagina birth; however, GBSurine 35-37 weeks does not perform satisfactorily as a standalone screening marker for risk of EOGBS. 
